At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 229 enrolled
Drug / intervention
Dexamethasone +2 moredrug
Likely dose
Dexamethasone 350 µg or 700 µg intravitreal injection at Day 0AI-extracted
Key inclusion· 2
- ✓Age 18 years or older
- ✓Diagnosis of chronic intermediate uveitis in at least one eye
Key exclusion· 2
- ✕Uncontrolled systemic disease
- ✕Any active ocular infections
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis
In Brief
A Phase 3 clinical trial evaluating Dexamethasone, dexamethasone, and 1 other intervention for Intermediate Uveitis and Posterior Uveitis. Completed, enrolled 229 participants across 18 sites in 18 countries.
Detailed Summary
This study will evaluate the safety and efficacy of an intravitreal implant of dexamethasone for the treatment of non-infectious intermediate or posterior uveitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntermediate Uveitis, Posterior Uveitis
CountriesAustralia, Austria, Brazil, Canada, Czechia, France, Germany, Greece, India, Israel, Poland, Portugal, South Africa, South Korea, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedJun 2006
Primary CompletionDec 2008
Study CompletionApr 2009
TodayJul 2026
First PostedJun 6, 2006
Enrollment StartMay 1, 2006
Primary CompletionDec 1, 2008
Study CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.1 years ago
Interventions
Dexamethasonedrug
Dexamethasone 350 µg; injection drug delivery system at Day 0
dexamethasonedrug
Dexamethasone 700 µg injection drug delivery system at Day 0
Sham injectiondrug
Sham injection at Day 0